Lupin appoints Paul McGarty as Prez, Lupin Pharmaceuticals

Mumbai, Aug 3 Pharma major, Lupin Ltd today announced the appointment of Paul McGarty as the President of its US subsidiary, Lupin Pharmaceuticals. McGarty has over 25-years experience in the pharmaceutical industry spanning across brand and specialty pharmaceutical companies, a press release issued here stated. Most recently, as the CEO of Nycomed US, McGarty successfully transformed the company from a topical manufacturer into a dermatology specialty company with a brand and generic business. Under his leadership, Nycomed US emerged as a leading fully-integrated dermatology specialty company in the US, the release said. He has also served as a member of the Executive Committee and Board of Directors for the Generic Pharmaceutical Association (GPhA), as well as a member of the National Association of Chain Drug Stores (NACDS) Foundation Board, the release said. "With more than 25 years of experience in pharmaceutical operations as well as commercial functions, in both generic and branded business, Paul brings invaluable experience and leadership skills to Lupin's growth plans in the US," Lupin Pharmaceuticals, Chief Executive Officer, Vinita Gupta, said.